Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Invested Capital (2016 - 2025)

Sutro Biopharma's Invested Capital history spans 10 years, with the latest figure at -$87.3 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 178.46% year-over-year to -$87.3 million; the TTM value through Sep 2025 reached -$87.3 million, down 178.46%, while the annual FY2024 figure was $44.6 million, 70.98% down from the prior year.
  • Invested Capital for Q3 2025 was -$87.3 million at Sutro Biopharma, down from -$32.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $310.6 million in Q2 2021 and bottomed at -$87.3 million in Q3 2025.
  • The 5-year median for Invested Capital is $164.9 million (2023), against an average of $157.6 million.
  • The largest annual shift saw Invested Capital skyrocketed 274.41% in 2021 before it crashed 178.46% in 2025.
  • A 5-year view of Invested Capital shows it stood at $261.9 million in 2021, then fell by 12.37% to $229.5 million in 2022, then plummeted by 33.04% to $153.7 million in 2023, then plummeted by 70.98% to $44.6 million in 2024, then crashed by 295.66% to -$87.3 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Invested Capital are -$87.3 million (Q3 2025), -$32.1 million (Q2 2025), and -$25.8 million (Q1 2025).